Recs: 3 Credit Suisse Friday, October 24, 2008 To receive this product, please specify your Credit Suisse
CELGene Corporation (CELG) Outperform M. Aberman CP: US$ 58.05 TP: US$ 74 CAP: US$ 27.1b In-Line Quarter, Remain Bullish, Raising Estimates and Lowering Target Price to $74 (from $84) Conclusion: While Celgene posted results that were "just" in-line, ...